sodium thiosulfate · Hope Pharms · NDA 020166, 203923
Sodium Thiosulfate
Earliest generic entry, as listed
29 Mar 2031
Blocked by patent: US 8496973.
Listed patents · 6 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 8496973 | substance, product, use U-1419 | 29 Mar 2031 |
| US 10479686 | product, use U-3390 | 7 Jul 2030 |
| US 9345724 | substance, product, use U-2015 | 7 Jul 2030 |
| US 9585912 | substance, product | 7 Jul 2030 |
| US 11753301 | substance, product, use U-3682 | 10 Feb 2030 |
| US 12304813 | product | 10 Feb 2030 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 2
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 020166 · 001 · RLD · discontinued | injectable, injection | 250MG/ML | open |
| 203923 · 001 · RLD | solution, intravenous | 12.5GM/50ML (250MG/ML) | 29 Mar 2031 |